ArticleJournal of asthma and allergy2026
Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Clinical trials have demonstrated benralizumab reduces exacerbations among patients with severe asthma. Evidence on the effectiveness of benralizumab among older adults is limited. The objective was to assess the change in the annual asthma exacerbation rate (AAER), exacerbation-related medical costs, and asthma medication utilization 12 months before and after the initiation of benralizumab in Medicare patients, as well as in an all-payer sample, in a subgroup with prior biologic use, and segmented by benralizumab adherence status. Methods: This was a single-arm, 12-month pre-/post-, within-subjects study using 2017-2023 MORE Results: The study included 4,611 Medicare patients and 7,706 patients in the all-payer sample. Among Medicare patients, there was a 43.5% reduction in AAER (mean [SD], 3.8[2.0] to 2.2[2.2] exacerbations per year; Conclusion: Medicare patients with severe asthma initiating benralizumab demonstrated meaningful reductions in AAER, exacerbation-related medical costs, and corticosteroid use in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.